EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)-Reference-Cited by-同舟云学术

EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)

Published:2007-05 Issue:5 Volume:2 Page:423-429
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Cappuzzo Federico,Ligorio Claudio,Toschi Luca,Rossi Elisa,Trisolini Rocco,Paioli Daniela,Magrini Elisabetta,Finocchiaro Giovanna,Bartolini Stefania,Cancellieri Alessandra,Hirsch Fred R.,Crino Lucio,Varella-Garcia Marileila

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference45 articles.

1. Cancer statistics;Greenlee;CA Cancer J Clin,2001

2. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials;Non-small cell Lung Cancer Collaborative Group;BMJ,1995

3. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002

4. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest Oncology Group trial;Kelly;J Clin Oncol,2001

5. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group;Hanna;J Clin Oncol,2004

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural Killer Cells in Lung Cancer;Interdisciplinary Cancer Research;2024

2. HER2 Alterations in Non-Small Cell Lung Cancer: Biologico-Clinical Consequences and Interest in Therapeutic Strategies;Life;2023-12-29

3. Management of HER2 alterations in non-small cell lung cancer – The past, present, and future;Lung Cancer;2023-12

4. Background of the need for targeted therapy options and platinum-based therapy responses in EGFR and ALK-mutated lung adenocarcinoma;Turkish Journal of Clinics and Laboratory;2023-09-30

5. Comprehensive Kinase Activity Profiling Revealed the Kinase Activity Patterns Associated with the Effects of EGFR Tyrosine Kinase Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients with Sensitizing EGFR Mutations;Proteomes;2023-02-05